Citations

Clear

3030 citation(s) found for "Susan, M".

Automation in the Clinical Microbiology Laboratory
Burnham, Carey‐Ann D. , Dunne, W. Michael , Novak, Susan, Patel, Robin , Greub, Gilbert , Patel, Robin , Burnham, C A

Mayo Clinic

Clinical Chemistry | May 21, 2013 | Volume: 59 | Issue: 12 | Pages: 1696-1702

10.1373/clinchem.2012.201038 | PMID 23690497 Get It

CUTE‐CV: A Prospective Study of Enhanced Left Atrial Appendage Visualization with Microbubble Contrast Agent Use during Transesophageal Echocardiography Guided Cardioversion
Bernier, Mathieu , Moir, William, Rain, Susan J. Eifert, Chandrasekaran, Krishnaswamy , Ammash, Naser M., Abdelmoneim, Sahar S. , Mulvagh, Sharon L.

Mayo Clinic

Echocardiography | May 11, 2013 | Volume: 30 | Issue: 9 | Pages: 1091-1097

10.1111/echo.12240 | PMID 23662846 Get It

ObjectivesThe aim of our study was to demonstrate that the use of contrast microbubbles during transesophageal echocardiography (TEE) guided cardioversion will improve interpretation of the TEE images.BackgroundTEE‐guided cardioversion of atrial flutter or fibrillation (AF) is a safe and proven method to restore sinus rhythm. However, artifacts and dense spontaneous echo contrast in the left atrial appendage (LAA) can sometimes decrease the level of confidence in excluding the presence of thrombus.MethodsOne hundred patients referred for TEE‐guided cardioversion were prospectively enrolled and microbubble contrast agent (DEFINITY) was administered after the clinical decision had been made regarding suitability for cardioversion. Noncontrast and contrast images were compared during subsequent offline analysis.ResultsLAA dimensions and contractility indices were higher, artifacts were significantly differentiated, previously unsuspected LAA filling defects were identified, and the level of confidence in excluding thrombus was enhanced in the contrast images when compared to the noncontrast images. After 4 months follow‐up, 1 stroke‐associated death occurred in a patient who had LAA thrombus recognized only by contrast. Left atrial appendage visualization is enhanced with microbubble contrast agent use during transesophageal echocardiography guided cardioversion and is useful in identification of intracardiac thrombus.
Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
Marcucci, Guido , Maharry, Kati , Metzeler, Klaus H. , Wu, Yue-Zhong, Mrózek, Krzysztof , Kohlschmidt, Jessica, Whitman, Susan P., Schwind, Sebastian , Becker, Heiko , Eisfeld, Ann‐Kathrin , Carroll, Andrew J. , Powell, Bayard L., Kolitz, Jonathan E. , Garzon, Ramiro , Stone, Richard M. , Bloomfield, Clara D. , Volinia, Stefano , Nicolet, Deedra , Mendler, Jason H. , Caligiuri, Michael A.

Mayo Clinic

Journal of Clinical Oncology | May 7, 2013 | Volume: 31 | Issue: 17 | Pages: 2086-2093

10.1200/jco.2012.45.6228 | PMID 23650424 Get It

Purpose To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA. Patients and Methods We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155–associated gene and microRNA expression profiles were derived using microarrays. Results Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-κB activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis. Conclusion miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML.
A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Tang, Weihong , Heit, John A. , Morange, Pierre‐Emmanuel , Pankratz, Nathan , Leebeek, Frank W.G. , Paré, Guillaume , Tzourio, Christophe , Basu, Saonli , Rose, Lynda M., Armasu, Sebastian M. , Lumley, Thomas, Heckbert, Susan R. , Uitterlinden, André G. , Lathrop, Mark, Cushman, Mary , Hofman, Albert , Lambert, Jean‐Charles , Glazer, Nicole L. , Pankow, James S. , Witteman, Jacqueline C.M., Amouyel, Philippe , Bis, Joshua C. , Bovill, Edwin G., Kong, Xiaoxiao , Boerwinkle, Eric , Trégouët, David‐Alexandre , Loth, Daan W. , Stricker, Bruno H. , Folsom, Aaron R. , Smith, Nicholas L. , Teichert, Martina , Chasman, Daniel I. , Guo, Li , Andrade, Mariza de , Psaty, Bruce M. , Ruiter, Rikje , Rice, Kenneth , Tracy, Russell P. , Rotter, Jerome I. , Ridker, Paul M. , Amouyel, Philippe , Tzourio, Christophe , Pankratz, Nathan , Pankow, James S , Tang, Weihong , Paré, Guillaume

Mayo Clinic

Genetic Epidemiology | May 5, 2013 | Volume: 37 | Issue: 5 | Pages: 512-521

10.1002/gepi.21731 | PMID 23650146 Get It

ABSTRACTVenous thromboembolism (VTE) is a common, heritable disease resulting in high rates of hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the coagulation pathway, have been established. To identify additional genetic determinants of VTE, we conducted a two‐stage genome‐wide association study (GWAS) among individuals of European ancestry in the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) VTE consortium. The discovery GWAS comprised 1,618 incident VTE cases out of 44,499 participants from six community‐based studies. Genotypes for genome‐wide single‐nucleotide polymorphisms (SNPs) were imputed to approximately 2.5 million SNPs in HapMap and association with VTE assessed using study‐design appropriate regression methods. Meta‐analysis of these results identified two known loci, in F5 and ABO. Top 1,047 tag SNPs (P ≤ 0.0016) from the discovery GWAS were tested for association in an additional 3,231 cases and 3,536 controls from three case‐control studies. In the combined data from these two stages, additional genome‐wide significant associations were observed on 4q35 at F11 (top SNP rs4253399, intronic to F11) and on 4q28 at FGG (rs6536024, 9.7 kb from FGG; P < 5.0 × 10−13 for both). The associations at the FGG locus were not completely explained by previously reported variants. Loci at or near SUSD1 and OTUD7A showed borderline yet novel associations (P < 5.0 × 10−6) and constitute new candidate genes. In conclusion, this large GWAS replicated key genetic associations in F5 and ABO, and confirmed the importance of F11 and FGG loci for VTE. Future studies are warranted to better characterize the associations with F11 and FGG and to replicate the new candidate associations.
Physical Health Status Measures Predict All-Cause Mortality in Patients With Heart Failure
Chamberlain, Alanna M. , McNallan, Sheila M, Spertus, John A. , Redfield, Margaret M. , Moser, Debra K. , Kane, Robert L , Weston, Susan A., Roger, Véronique L. , Dunlay, Shannon M. , Chamberlain, Alanna M , Spertus, John A

Mayo Clinic

Circulation: Heart Failure | April 26, 2013 | Volume: 6 | Issue: 4 | Pages: 669-675

10.1161/circheartfailure.112.000291 | PMID 23625946 Get It

Background— Physical health status measures have been shown to predict death in heart failure (HF); however, few studies found significant associations after adjustment for confounders, and most were not representative of all HF patients. Methods and Results— HF patients from southeastern MN were prospectively enrolled between 10/2007 and 12/2010, completed a 12-item Short Form Health Survey (SF-12) and a 6-minute walk, and were followed through 2011 for death from any cause. Scores ≤25 on the SF-12 physical component indicated low self-reported physical functioning, and the first question of the SF-12 measured self-rated general health. Low functional exercise capacity was defined as ≤300 m walked during a 6-minute walk. Over a mean follow-up of 2.3 years, 86 deaths occurred among the 352 participants. A 1.6-fold (95% confidence interval, 1.0–2.7) and 1.8-fold (95% confidence interval, 1.1–2.9) increased risk of death was observed among patients with low self-reported physical functioning and low functional exercise capacity, respectively. Poor self-rated general health corresponded to a 2.7-fold (95% confidence interval, 1.5–4.9) increased risk of death compared with good to excellent general health. All measures equally discriminated between who would die and who would survive (C-statistics: 0.729, 0.750, and 0.740 for self-reported physical functioning, self-rated general health, and functional exercise capacity, respectively). Conclusions— Three physical health status measures, captured by the SF-12 and a 6-minute walk, equally predict death among community HF patients. Therefore, the first question of the SF-12, which is the least burdensome to administer, may be sufficient to identify HF patients at greatest risk of death.
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein–Barr virus status
Ghesquières, Hervé , Link, Brian K. , Maurer, Matthew J. , Cunningham, Julie M. , Novak, Anne J. , Larrabee, Beth R. , Allmer, Cristine, Ansell, Stephen M. , Cerhan, James R. , Doǧan, Ahmet , Slager, Susan L. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

Leukemia & Lymphoma | April 19, 2013 | Volume: 54 | Issue: 11 | Pages: 2571-2573

10.3109/10428194.2013.796048 | PMID 23597143 Get It

Thirty-Day Rehospitalizations After Acute Myocardial Infarction
Weston, Susan A., Killian, Jill M. , Bell, Malcolm R. , Jaffe, Allan S. , Roger, Véronique L. , Dunlay, Shannon M. , Jaffe, Allan S.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 157 | Issue: 1 | Pages: 11-18

10.7326/0003-4819-157-1-201207030-00004 | PMID 22751756 Get It

A Community-Based Study of Stroke Incidence after Myocardial Infarction
Witt, Brandi J., Brown, Robert D., Jacobsen, Steven J. , Weston, Susan A., Yawn, Barbara P. , Roger, Véronique L.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 143 | Issue: 11 | Pages: 785-792

10.7326/0003-4819-143-11-200512060-00006 | PMID 16330789 Get It

Innovations in Access to Care: A Patient-Centered Approach
Seiders, Kathleen, Wilder, Susan S., Berry, Leonard L.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 139 | Issue: 7 | Pages: 568-574

10.7326/0003-4819-139-7-200310070-00009 | PMID 14530228 Get It

Trends in the Incidence and Survival of Patients with Hospitalized Myocardial Infarction, Olmsted County, Minnesota, 1979 to 1994
Roger, Véronique L. , Jacobsen, Steven J. , Weston, Susan A., Goraya, Tauqir, Killian, Jill M. , Reeder, Guy S., Yawn, Barbara P. , Frye, Robert L. , Kottke, Thomas E.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 136 | Issue: 5 | Pages: 341-348

10.7326/0003-4819-136-5-200203050-00005 | PMID 11874305 Get It